|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
-Producing CD4+ T Cell Clones Following Immune Reconstitution on Highly Active Antiretroviral Therapy1




Departments of
* Immunology and
Medicine, University of Colorado Health Sciences Center, Denver, CO 80262; and
Epimmune, San Diego, CA 92121
HIV-1 Ag-specific CD4+ T cell proliferative responses
in human subjects with advanced, untreated HIV-1 disease are often weak
or undetectable. Conversely, HIV-1-specific CD4+ T cell
proliferation is occasionally detected following suppression of HIV-1
replication with highly active antiretroviral therapy (HAART). These
observations suggest that unchecked HIV-1 replication may lead to
depletion or dysfunction of HIV-1-specific CD4+ T cells,
and that these defects may be partially corrected by viral suppression
and subsequent immune reconstitution. However, the impact of this
immune reconstitution on the repertoire of HIV-1-specific
CD4+ T cells has not been thoroughly evaluated. To examine
the HIV-1-specific CD4+ T cell repertoire in this clinical
setting, we established HIV-1 p24-specific CD4+ T cell
clones from a successfully HAART-treated subject whose pretreatment
peripheral CD4 count was 0 cells/µl. Eleven different p24-specific
CD4+ T cell clonotypes were distinguished among 13 clones
obtained. Most clones produced both IFN-
and IL-4 upon Ag
stimulation. Clones targeted eight distinct epitopes that varied in
their conservancy among HIV-1 strains, and responses were restricted by
one of three MHC II molecules. Clones showed a range of functional
avidities for both protein and peptide Ags. Additional studies
confirmed that multiple HIV-1 p24-derived epitopes were targeted by
IFN-
-producing CD4+ cells from subjects first treated
with HAART during advanced HIV-1 disease (median, 4.5 peptides/subject;
range, 36). These results suggest that in HAART-treated subjects
whose peripheral CD4+ T cell pools were once severely
depleted, the HIV-1-specific CD4+ T cell repertoire may
include a diverse array of clonotypes targeting multiple HIV-1
epitopes.
This article has been cited by other articles:
![]() |
C. C. Wilson, M. J. Newman, B. D. Livingston, S. MaWhinney, J. E. Forster, J. Scott, R. T. Schooley, and C. A. Benson Clinical Phase 1 Testing of the Safety and Immunogenicity of an Epitope-Based DNA Vaccine in Human Immunodeficiency Virus Type 1-Infected Subjects Receiving Highly Active Antiretroviral Therapy Clin. Vaccine Immunol., June 1, 2008; 15(6): 986 - 994. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Miles, D. Elhassen, N. A. Borg, S. L. Silins, F. E. Tynan, J. M. Burrows, A. W. Purcell, L. Kjer-Nielsen, J. Rossjohn, S. R. Burrows, et al. CTL Recognition of a Bulged Viral Peptide Involves Biased TCR Selection J. Immunol., September 15, 2005; 175(6): 3826 - 3834. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Boritz, B. E. Palmer, and C. C. Wilson Human Immunodeficiency Virus Type 1 (HIV-1)-Specific CD4+ T Cells That Proliferate In Vitro Detected in Samples from Most Viremic Subjects and Inversely Associated with Plasma HIV-1 Levels J. Virol., November 15, 2004; 78(22): 12638 - 12646. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Zavala-Ruiz, I. Strug, B. D. Walker, P. J. Norris, and L. J. Stern A hairpin turn in a class II MHC-bound peptide orients residues outside the binding groove for T cell recognition PNAS, September 7, 2004; 101(36): 13279 - 13284. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Pajot, V. Pancre, N. Fazilleau, M.-L. Michel, G. Angyalosi, D. M. Ojcius, C. Auriault, F. A. Lemonnier, and Y.-C. Lone Comparison of HLA-DR1-restricted T cell response induced in HLA-DR1 transgenic mice deficient for murine MHC class II and HLA-DR1 transgenic mice expressing endogenous murine MHC class II molecules Int. Immunol., September 1, 2004; 16(9): 1275 - 1282. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Kaufmann, P. M. Bailey, J. Sidney, B. Wagner, P. J. Norris, M. N. Johnston, L. A. Cosimi, M. M. Addo, M. Lichterfeld, M. Altfeld, et al. Comprehensive Analysis of Human Immunodeficiency Virus Type 1-Specific CD4 Responses Reveals Marked Immunodominance of gag and nef and the Presence of Broadly Recognized Peptides J. Virol., May 1, 2004; 78(9): 4463 - 4477. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |